Skip to menu Skip to content Skip to footer

2012

Journal Article

Recommendations for standardized reporting of protein electrophoresis in Australia and New Zealand

Tate, Jillian, Caldwell, Grahame, Daly, James, Gillis, David, Jenkins, Margaret, Jovanovich, Sue, Martin, Helen, Steele, Richard, Wienholt, Louise and Mollee, Peter (2012). Recommendations for standardized reporting of protein electrophoresis in Australia and New Zealand. Annals of Clinical Biochemistry, 49 (3), 242-256. doi: 10.1258/acb.2011.011158

Recommendations for standardized reporting of protein electrophoresis in Australia and New Zealand

2012

Journal Article

WT1 expression as a marker of minimal residual disease predicts outcome in acute myeloid leukemia when measured post-consolidation

Gray, James X., McMillen, Lyle, Mollee, Peter, Paul, Sanjoy, Lane, Steven, Bird, Robert, Gill, Devinder, Saal, Russell and Marlton, Paula (2012). WT1 expression as a marker of minimal residual disease predicts outcome in acute myeloid leukemia when measured post-consolidation. Leukemia Research, 36 (4), 453-458. doi: 10.1016/j.leukres.2011.09.005

WT1 expression as a marker of minimal residual disease predicts outcome in acute myeloid leukemia when measured post-consolidation

2012

Journal Article

Validation of whole blood impedance aggregometry as a new diagnostic tool for HIT: results of a large Australian study

Morel-Kopp, Marie-Christine, Tan, Chee Wee, Brighton, Timothy A., McRae, Simon, Baker, Ross, Huyen Tran, Mollee, Peter, Kershaw, Geoffrey, Joseph, Joanne and Ward, Christopher (2012). Validation of whole blood impedance aggregometry as a new diagnostic tool for HIT: results of a large Australian study. Thrombosis and Haemostasis, 107 (3), 575-583. doi: 10.1160/TH11-09-0631

Validation of whole blood impedance aggregometry as a new diagnostic tool for HIT: results of a large Australian study

2012

Journal Article

Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): The prospective international multicentre phase 2 PTLD-1 trial

Trappe, Ralf, Oertel, Stephan, Leblond, Veronique, Mollee, Peter, Sender, Monica, Reinke, Petra, Neuhaus, Ruth, Lehmkuhl, Hans, Horst, Heinz August, Salles, Gilles, Morschhauser, Franck, Jaccard, Arnaud, Lamy, Thierry, Leithäuser, Malte, Zimmermann, Heiner, Anagnostopoulos, Ioannis, Raphael, Martine, Riess, Hanno, Choquet, Sylvain and for the German PTLD Study Group and the European PTLD Network (2012). Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): The prospective international multicentre phase 2 PTLD-1 trial. The Lancet Oncology, 13 (2), 196-206. doi: 10.1016/S1470-2045(11)70300-X

Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): The prospective international multicentre phase 2 PTLD-1 trial

2012

Journal Article

High dose methotrexate and extended hours high-flux hemodialysis for the treatment of primary central nervous system lymphoma in a patient with end stage renal disease

Mutsando, Howard, Fahim, Magid, Gill, Devinder S., Hawley, Carmel M., Johnson, David W., Maher, K. Gandhi, Marlton, Paula V., Mar Fan, Helen G. and Mollee, Peter N. (2012). High dose methotrexate and extended hours high-flux hemodialysis for the treatment of primary central nervous system lymphoma in a patient with end stage renal disease. American Journal of Blood Research, 2 (1), 66-70.

High dose methotrexate and extended hours high-flux hemodialysis for the treatment of primary central nervous system lymphoma in a patient with end stage renal disease

2012

Conference Publication

Outcomes and prognostic factors for patients with Acute Myeloid Leukemia admitted to the intensive care unit

Jackson, Kathryn A., Mollee, Peter, Morris, Kirk, Jackson, Dwane L., Kruger, Peter, Klein, Kerenaftali and Kennedy, Glen A. (2012). Outcomes and prognostic factors for patients with Acute Myeloid Leukemia admitted to the intensive care unit. 54th Annual Meeting and Exposition of the American Society of Hematology (ASH), Atlanta, GA, United States, 8-11 December 2012. Washington, DC, United States: American Society of Hematology. doi: 10.1182/blood.V120.21.3613.3613

Outcomes and prognostic factors for patients with Acute Myeloid Leukemia admitted to the intensive care unit

2012

Conference Publication

Intensive Chemotherapy for Acute Myeloid Leukemia in Elderly Patients

Jackson, Kathryn A., Kennedy, Glen A., Mollee, Peter and Morris, Kirk (2012). Intensive Chemotherapy for Acute Myeloid Leukemia in Elderly Patients. 54th Annual Meeting and Exposition of the American Society of Hematology (ASH), Atlanta, GA, United States, 8-11 December 2012. Washington, DC, United States: American Society of Hematology.

Intensive Chemotherapy for Acute Myeloid Leukemia in Elderly Patients

2011

Conference Publication

ZAP-70 expression measured by quantitative PCR (QPCR) as a prognostic marker in chronic lymphocytic leukaemia (CLL)

Mollee, Peter, Banh, Raymond H., Cheung, Catherine, Saal, Russell, Chambers, Lynne, Pelly, Tennille and Gill, Devinder S (2011). ZAP-70 expression measured by quantitative PCR (QPCR) as a prognostic marker in chronic lymphocytic leukaemia (CLL). 53rd ASH Annual Meeting, San Diego, 10-13 December 2011. American Society of Hematology. doi: 10.1182/blood.v118.21.4602.4602

ZAP-70 expression measured by quantitative PCR (QPCR) as a prognostic marker in chronic lymphocytic leukaemia (CLL)

2011

Conference Publication

Tissue microarray in DLBCL patients receiving R-CHOP chemo-immunotherapy shows survival benefit for coexpression of LMO2/BCL6

Keane, Colm, Shen, Linda, Han, Erica, Nourse, Jamie P, Lea, Rod, Mollee, Peter, Gill, Devinder S and Gandhi, Maher K (2011). Tissue microarray in DLBCL patients receiving R-CHOP chemo-immunotherapy shows survival benefit for coexpression of LMO2/BCL6. 53rd ASH Annual Meeting, San Diego, 10-13 December 2011. American Society of Hematology. doi: 10.1182/blood.v118.21.1585.1585

Tissue microarray in DLBCL patients receiving R-CHOP chemo-immunotherapy shows survival benefit for coexpression of LMO2/BCL6

2011

Conference Publication

A phase II study of risk-adapted intravenous melphalan in patients with AL amyloidosis

Mollee, Peter, Tiley, Campbell, Cunningham, Ilona, Moore, John, Prince, Miles, Cannell, Paul, Gibbons, Steve, Tate, Jill, Paul, Sanjoy and Gill, Devinder S (2011). A phase II study of risk-adapted intravenous melphalan in patients with AL amyloidosis. 53rd ASH Annual Meeting, San Diego, 10-13 December 2011. American Society of Hematology. doi: 10.1182/blood.v118.21.3973.3973

A phase II study of risk-adapted intravenous melphalan in patients with AL amyloidosis

2011

Journal Article

Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly expresses EBNA3A with conserved CD8 T-cell epitopes

Nguyen-Van, Do, Keane, Colm, Han, Erica, Jones, Kimberley, Nourse, Jamie P., Vari, Frank, Ross, Nathan, Crooks, Pauline, Ramuz, Olivier, Green, Michael, Griffith, Lyn, Trappe, Ralf, Grigg, Andrew, Mollee, Peter and Gandhi, Maher K. (2011). Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly expresses EBNA3A with conserved CD8 T-cell epitopes. American Journal of Blood Research, 1 (2), 146-159.

Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly expresses EBNA3A with conserved CD8 T-cell epitopes

2011

Journal Article

Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial

Coiffier, Bertrand, Osmanov, Evgenii A., Hong, Xiaonan, Scheliga, Adriana, Mayer, Jiri, Offner, Fritz, Rule, Simon, Teixeira, Adriana, Walewski, Jan, de Vos, Sven, Crump, Michael, Shpilberg, Ofer, Esseltine, Dixie-Lee, Zhu, Eugene, Enny, Christopher, Theocharous, Panteli, van de Velde, Helgi, Elsayed, Yusri A., Zinzani, Pier Luigi, LYM-3001 study investigators and Mollee, Peter (2011). Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial. The Lancet Oncology, 12 (8), 773-84. doi: 10.1016/S1470-2045(11)70150-4

Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial

2011

Journal Article

Catheter-associated bloodstream infection incidence and risk factors in adults with cancer: A prospective cohort study

Mollee, P., Jones, M., Stackelroth, J., van Kuilenburg, R., Joubert, W., Faoagali, J., Looke, D., Harper, J. and Clements, A. (2011). Catheter-associated bloodstream infection incidence and risk factors in adults with cancer: A prospective cohort study. Journal of Hospital Infection, 78 (1), 26-30. doi: 10.1016/j.jhin.2011.01.018

Catheter-associated bloodstream infection incidence and risk factors in adults with cancer: A prospective cohort study

2011

Journal Article

Prognostic utility of spontaneous erythroid colony formation and JAK2 mutational analysis for thrombotic events in essential thrombocythaemia

Weston, H., Cowell, V., Grimmett, K., Saal, R., Jones, M., Mills, T., Gill, D., Marlton, P., Bird, R. and Mollee, P. (2011). Prognostic utility of spontaneous erythroid colony formation and JAK2 mutational analysis for thrombotic events in essential thrombocythaemia. Internal Medicine Journal, 41 (5), 408-415. doi: 10.1111/j.1445-5994.2010.02334.x

Prognostic utility of spontaneous erythroid colony formation and JAK2 mutational analysis for thrombotic events in essential thrombocythaemia

2011

Conference Publication

Recommendations for Standardised Reporting of Protein Electrophoresis in Australia and New Zealand

Tate, J., Mollee, P., Caldwell, G., Daly, J., Gillis, D., Jenkins, M., Jovanovich, S., Martin, H., Steele, R., Wienholt, L. and AACB Working Party Standardised Reporting of Protein Electrophoresis (2011). Recommendations for Standardised Reporting of Protein Electrophoresis in Australia and New Zealand. EuroMedLab Berlin 2011, Berlin, Germany, 15-19 May 2011. Berlin, Germany: Walter De Gruyter. doi: 10.1515/CCLM.2011.527

Recommendations for Standardised Reporting of Protein Electrophoresis in Australia and New Zealand

2011

Journal Article

Outcome of treatment of adult acute lymphoblastic leukemia with hyperfractionated cyclophosphamide, doxorubicin, vincristine, dexamethasone/methotrexate, cytarabine: Results from an Australian population

Morris, Kirk, Weston, Helen, Mollee, Peter, Marlton, Paula, Gill, Devinder and Kennedy, Glen (2011). Outcome of treatment of adult acute lymphoblastic leukemia with hyperfractionated cyclophosphamide, doxorubicin, vincristine, dexamethasone/methotrexate, cytarabine: Results from an Australian population. Leukemia and Lymphoma, 52 (1), 85-91. doi: 10.3109/10428194.2010.532889

Outcome of treatment of adult acute lymphoblastic leukemia with hyperfractionated cyclophosphamide, doxorubicin, vincristine, dexamethasone/methotrexate, cytarabine: Results from an Australian population

2011

Conference Publication

Tissue Microarray in DLBCL Patients receiving R-CHOP Chemo-Immunotherapy Shows Survival Benefit for Coexpression of LMO2/BCL6

Keane, C, Shen, L, Han, E, Nourse, JP, Lea, R, Mollee, P, Gill, DS and Gandhi, MK (2011). Tissue Microarray in DLBCL Patients receiving R-CHOP Chemo-Immunotherapy Shows Survival Benefit for Coexpression of LMO2/BCL6. 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), San Diego Ca, Dec 10-13, 2011. WASHINGTON: AMER SOC HEMATOLOGY.

Tissue Microarray in DLBCL Patients receiving R-CHOP Chemo-Immunotherapy Shows Survival Benefit for Coexpression of LMO2/BCL6

2011

Journal Article

Proteomics in molecular diagnosis: typing of amyloidosis

Loo, Dorothy, Mollee, Peter N., Renaut, Patricia and Hill, Michelle M. (2011). Proteomics in molecular diagnosis: typing of amyloidosis. Journal of Biomedicine and Biotechnology, 2011 (1) 754109, 754109.1-754109.9. doi: 10.1155/2011/754109

Proteomics in molecular diagnosis: typing of amyloidosis

2011

Conference Publication

Rapid diagnosis of heparin-induced thrombocytopenia (HIT) by whole blood impedance aggregometry: results of the Australian multi centre study

Morel-Kopp, MC, Tan, CW, Brighton, T, McRae, S, Tran, H, Mollee, P, Kershaw, G, Joseph, J, Coyle, L and Ward, C (2011). Rapid diagnosis of heparin-induced thrombocytopenia (HIT) by whole blood impedance aggregometry: results of the Australian multi centre study. Unknown, unknown, unknown. HOBOKEN: WILEY-BLACKWELL.

Rapid diagnosis of heparin-induced thrombocytopenia (HIT) by whole blood impedance aggregometry: results of the Australian multi centre study

2011

Conference Publication

A Phase II study of risk-adapted intravenous melphalan in patients with AL amyloidosis

Mollee, Peter, Tiley, Campbell, Cunningham, Ilona, Moore, John, Prince, Miles, Cannell, Paul, Gibbons, Steve, Tate, Jill, Paul, Sanjoy and Gill, Devinder S. (2011). A Phase II study of risk-adapted intravenous melphalan in patients with AL amyloidosis. 53rd Annual Meeting and Exposition of the American Society of Hematology (ASH), San Diego, CA, United States, Dec 10-13, 2011. Washington, DC, United States: American Society of Hematology.

A Phase II study of risk-adapted intravenous melphalan in patients with AL amyloidosis